PAPER Lorenz R, Samnick S, Dillmann U, Schiller M, Ong MF, Faßbender K, Buck A, Spiegel J
SEARCH RESULTS
329940 RESULTS
PAPER Ma J, Choi BR, Chung C, Min SS, Jeon WK, Han JS
Chronic brain inflammation causes a reduction in GluN2A and GluN2B subunits of NMDA receptors and an increase in the phosphorylation of mitogen-activated protein kinases in the hippocampus.
Mol Brain. 2014 Apr 24;7:33. PubMed: 24761931Julian Pei
University of PennsylvaniaLansdale, United States
Maria Jose Sanchez Artero
PsiquiatriaGuadalajara, Spain
Does PET Tracer Reveal Severity of Parkinson's?
RESEARCH NEWS 2014-04-26 Research News In order to gauge the effectiveness of disease-modifying therapies for Parkinson’s, researchers are looking for a biomarker that measures how far a person’s disease has advanced. In the April 21 JAMA Neurology, scientists led by Kun-Ju Lin a
PAPER Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ
Correlation of Parkinson Disease Severity and 18F-DTBZ Positron Emission Tomography.
JAMA Neurol. 2014 Jun 1;71(6):758-66. PubMed: 24756323PAPER Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Ann Neurol. 1996 Dec;40(6):873-84. PubMed: 9007092PAPER de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ
Visualizing vesicular dopamine dynamics in Parkinson's disease.
Synapse. 2009 Aug;63(8):713-6. PubMed: 19391152Muscle-Boosting Therapy Fails in Phase 2 Trial for ALS
RESEARCH NEWS 2014-04-26 Research News The experimental muscle-stimulating drug Tirasemtiv was unable to improve amyotrophic lateral sclerosis (ALS) symptoms in a Phase 2 clinical trial, according to top-line data. Announced April 25 by the drug’s developer, South San Francisco-b
PAPER Shefner JM, Watson ML, Meng L, Wolff AA, Neals/Cytokinetics STUDY Team
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. Epub 2013 Aug 19 PubMed: 23952636PAPER Winblad B, Kivipelto M, Andersen P, Johansson G, Andreasen N
[Treatment of early stages of Alzheimer's disease: New guidelines are in the pipeline].
Lakartidningen. 2013 Sep 11-17;110(37):1613. PubMed: 24163935PAPER Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, Tan J, Giunta B
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
PLoS One. 2014;9(4):e95500. Epub 2014 Apr 23 PubMed: 24759994PAPER Liu MX, Liu JG, Li H
[Chinese materia medica monomers and components research progress on treating Alzheimer's disease by targeting gamma-secretase].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Mar;34(3):376-9. PubMed: 24758094PAPER Jung Y, Dickson DW, Murray ME, Whitwell JL, Knopman DS, Boeve BF, Jack CR Jr, Parisi JE, Petersen RC, Josephs KA
TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism.
J Neurol. 2014 Jul;261(7):1344-8. Epub 2014 Apr 24 PubMed: 24760339PAPER Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, Zagol-Ikapitte I, Boutaud O, Andreasson KI
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling.
J Neurosci. 2014 Apr 23;34(17):5882-94. PubMed: 24760848Current Filters
No filters selected